Category Archives: IP

Myriad Decision: Praise and Perils for Biotechnology Patent Policy

The Supreme Court decision blocking patents on naturally-occurring genes has generated predictions of doom for biotech innovation, along with expectations of more healthy competition in discovering new treatments and diagnostics. Although some commentators regarded the decision, Association for Molecular Pathology v. Myriad Genetics, as a “major reversal” in longstanding patent policy, many leaders of the […]
Also posted in Biotech, Gene therapy, Legal, Technology | Tagged , , , , | 2 Comments

Medicines Patent Pool: Industry's Toe Still in the Water

At a time when Big Pharma is struggling with new business models geared to the demands of a changing marketplace, the Medicines Patent Pool (MPP) is offering a way forward through voluntary licensing and patent deals that it insists will deliver what the drug majors say they want: more innovation; better market access; and the […]
Also posted in healthcare | Tagged , , , , | Leave a comment

First 'Real' European Patent Imminent

It’s exciting times for patents in Europe. Not everyone’s excitement is pleasurable, but there’s certainly plenty going on, writes Reflector, Pharm Exec‘s EU correspondent. Much of the excitement is linked to the imminent advent of Europe’s first real European patent. After decades of failed attempts, by the beginning of 2014 the European Union will finally […]
Also posted in Europe, Guest Blog | Tagged , , , , , | 1 Comment

PhRMA Dismayed by Global IPR Report

Also posted in Global, Guest Blog, Regulatory | Tagged , , , | Leave a comment

Drug Pipelines in Canada: Is There a Buyer for Future Innovation?

Last week, Canada’s National Prescription Drug Utilization Information System (NPDUIS), a federal-provincial fact-finding panel that works closely with the Patented Medicines Prices Review Board (PMPRB), issued its fourth New Drug Pipeline Monitor (NDPM) looking at drugs currently under development that may have an impact on future drug expenditures. The report is another example of how […]
Also posted in Global, healthcare, Market Access, Orphan Drugs, pricing, R&D, Regulatory | Tagged , , , , , | Leave a comment
  • Categories

  • Meta